Molecular interplay between Δ5/Δ6 desaturases and long-chain fatty acids in the pathogenesis of non-alcoholic steatohepatitis

Gut

Volumn 63, Issue 2, 2014, Pages 344-355

  López Vicario, Cristina ^a   González Périz, Ana ^a,b   Rius, Bibiana ^a   Morán Salvador, Eva ^a   García Alonso, Verónica ^a   Lozano, Juan José ^b   Bataller, Ramón ^c   Cofán, Montserrat ^a,d   Kang, Jing X ^e   Arroyo, Vicente ^a,b   Clària, Joan ^a,b,f   Titos, Esther ^a,b  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d Instituto de Salud Carlos III   (Spain)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL COENZYME A DESATURASE 1; LINOLEOYL COENZYME A DESATURASE; LONG CHAIN FATTY ACID; OLIGONUCLEOTIDE; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DELTA 5 DESATURASE GENE; DELTA 6 DESATURASE GENE; FATTY ACID DESATURATION; FATTY ACID TRANSPORT; FEMALE; GAS CHROMATOGRAPHY; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; INSULIN RESISTANCE; LIPID PEROXIDATION; LIPID STORAGE; LIPOGENESIS; LIVER BIOPSY; LIVER CELL; MACROPHAGE; MALE; MICROARRAY ANALYSIS; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TRANSLATIONAL RESEARCH; UPREGULATION;

EID: 84891737631     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2012-303179     Document Type: Article

References (43)

1. Sanyal AJ. Mechanisms of Disease: pathogenesis of nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2005;2 46-53. (Pubitemid 40812527)
2. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346 1221-31.
3. Jou J, Choi SS, Diehl AM. Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis 2008;28 370-9.
4. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006;43 99-112.
5. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation and insulin resistance. Gastroenterology 2007;132 2169-80.
6. Nakamura MT, Nara TY. Structure, function, and dietary regulation of Δ6, Δ5 and Δ9 desaturases. Ann Rev Nutr 2004;24 345-76. (Pubitemid 38938796)
7. Calder PC. Polyunsaturated fatty acids and inflammation. Prostaglandins Leukot Essent Fatty Acids 2006;75 197-202. (Pubitemid 44292527)
8. Samuelsson B, Dahlén SE, Lindgren JA, et al. Leukotrienes and lipoxins: structures, biosynthesis and biological effects. Science 1987;237 1171-6. (Pubitemid 17131222)
9. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008;8 349-61. (Pubitemid 351595216)
10. Ashburner M, Ball CA, Blake JA, et al. The Gene Ontology Consortium. Gene ontology: tool for the unification of biology. Nat Genet 2000;25 25-9. (Pubitemid 30257031)
11. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005;102 15545-50. (Pubitemid 41528093)
12. Kang JX, Wang J, Wu L, et al. Fat-1 mice convert n-6 to n-3 fatty acids. Nature 2004;427 504. (Pubitemid 38209102)
13. Martínez-Clemente M, Ferré N, González-Périz A, et al. 5-lipoxygenase deficiency reduces hepatic inflammation and TNFalpha-induced hepatocyte damage in hyperlipidemia-prone ApoE-null mice. Hepatology 2010;51 817-27.
14. Morán-Salvador E, López-Parra M, García-Alonso V, et al. Role for PPAR-gamma in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts. FASEB J 2011;25 2538-50.
15. Gómez-Lechón MJ, Donato MT, Martínez-Romero A, et al. A human hepatocellular in vitro model to investigate steatosis. Chem Biol Interact 2007;165 106-16. (Pubitemid 46072796)
16. Olinga P, Merema MT, de Jager MH, et al. Rat liver slices as a tool to study LPS-induced inflammatory response in the liver. J Hepatol 2001;35 187-94. (Pubitemid 32803473)
17. Obukowicz MG, Raz A, Pyla PD, et al. Identification and characterization of a novel delta6/delta5 fatty acid desaturase inhibitor as a potential anti-inflammatory agent. Biochem Pharmacol 1998;55 1045-58. (Pubitemid 28167726)
18. Koeberle A, Shindou H, Harayama T, et al. Palmitoleate is a mitogen, formed upon stimulation with growth factors, and converted to palmitoleoyl-phosphatidylinositol. J Biol Chem 2012;287 27244-54.
19. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957;226 497-509.
20. Czaja MJ. JNK regulation of hepatic manifestations of the metabolic syndrome. Trends Endocrinol Metab 2010;21 707-13.
21. Yamaguchi K, Yang L, McCall S, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007;45 1366-74. (Pubitemid 46918320)
22. Schmitz G, Ecker J. The opposing effects of n-3 and n-6 fatty acids. Prog Lipid Res 2008;47 147-55.
23. Wallis JG, Watts JL, Browse J. Polyunsaturated fatty acid synthesis: what will they think of next? Trends. Biochem Sci 2002;27 467-73. (Pubitemid 35246256)
24. Puri P, Baillie RA, Wiest MM, et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007;22 2118-23.
25. Puri P, Wiest MM, Cheung O, et al. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology 2009;50 1827-38.
26. Araya J, Rodrigo R, Videla LA, et al. Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci 2004;106 635-43. (Pubitemid 38797577)
27. Barr J, Vázquez-Chantada M, Alonso C, et al. Liquid chromatography-mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease. J Proteome Res 2010;9 4501-12.
28. Kang JX. Fat-1 transgenic mice: a new model for omega-3 research. Prostaglandins Leukot Essent Fatty Acids 2007;77 263-7. (Pubitemid 350198864)
29. Ji S, Hardy RW, Wood PA. Transgenic expression of n-3 fatty acid desaturase (fat-1) in C57/BL6 mice: Effects on glucose homeostasis and body weight. J Cell Biochem 2009;107 809-17.
30. White PJ, Arita M, Taguchi R, et al. Transgenic restoration of long-chain n-3 fatty acids in insulin target issues improves resolution capacity and alleviates obesity-linked inflammation and insulin resistance in high-fat-fed mice. Diabetes 2010;59 3066-73.
31. Rahman MM, Halade GV, Bhattacharya A, et al. The fat-1 transgene in mice increases antioxidant potential, reduces pro-inflammatory cytokine levels, and enhances PPAR? and SIRT-1 expression on a calorie restricted diet. Oxid Med Cell Longev 2009;2 307-16.
32. Leung T-M, Nieto N. CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease. J Hepatol 2013;58 395-8.
33. Hagopian K, Weber KL, Hwee DT, et al. Complex I-associated hydrogen peroxide production is decreased and electron transport chain enzyme activities are altered in n-3 enriched fat-1 mice. PLoS One 2010;5:e12696.
34. Araya J, Rodrigo R, Pettinelli P, et al. Decreased liver fatty acid delta-6 and delta-5 desaturase activity in obese patients. Obesity 2010;18 1460-3.
35. Warensjö E, Ohrvall M, Vessby B. Fatty acid composition estimated desaturase activities associated with obesity and lifestyle variables in men and women. Nutr Metab Cardiovasc Dis 2006 16:128-36. (Pubitemid 43384710)
36. Matsuzaka T, Shimano H, Yahagi N, et al. Crucial role of a long-chain fatty acid elongase, Elovl6, in obesity-induced insulin resistance. Nat Med 2007;13 1193-202. (Pubitemid 47530641)
37. Matsuzaka T, Atsumi A, Matsumori R. Elovl6 promotes nonalcoholic steatohepatitis. Hepatology 2012;56 2199-208.
38. Hellmann J, Tang Y, Kosuri M, et al. Resolvin D1 decreases adipose tissue macrophage accumulation and improves insulin sensitivity in obese-diabetic mice. FASEB J 2011;25 2399-407.
39. González-Périz A, Horrillo R, Ferré N, et al. Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J 2009;23 1946-57.
40. Hudert CA, Weylandt KH, Lu Yan, et al. Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc Natl Acad Sci USA 2006;103 11276-81. (Pubitemid 44156509)
41. Parker HM, Johnson NA, Burdon CA. Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Hepatol 2012;56 944-51.
42. Masterton GS, Plevris JN, Hayes PC. Review article: omega-3 fatty acids-a promising novel therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2010;31 679-92.
43. El-Badry AM, Graf R, Clavien PA. Omega-3-Omega-6: What is right for the liver? J Hepatol 2007;47 718-25.